TY - JOUR
T1 - Corrigendum to “Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease” [Am Heart J (2021) 231:36–44, (American Heart Journal (2021) 231(36-44) (S0002870320303410), (10.1016/j.ahj.2020.10.055))
AU - Shavadia, Jay S.
AU - Wilson, Jonathan
AU - Edmonston, Daniel
AU - Platt, Alyssa
AU - Ephraim, Patti
AU - Hall, Rasheeda
AU - Goldstein, Benjamin A.
AU - Boulware, L. Ebony
AU - Peterson, Eric
AU - Pendergast, Jane
AU - Scialla, Julia J.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/11
Y1 - 2022/11
N2 - The authors regret that a typographical error and merge error was identified in the generation of the original dataset for this analysis. As a result, there is a change in the total event numbers for the primary outcome of fatal and nonfatal myocardial infarction or stroke and all-cause mortality. On page 3, under the subtitle “Primary and secondary outcomes”, the text related to these outcomes should read: “Over a median of 622 days (interquartile range spanning 299-1,224 days) in the propensity-matched population, statin use was not associated with the composite risk for fatal or nonfatal myocardial infarction or stroke (11,632 vs 11,047 events, hazard ratio [HR] 0.99, 95% CI 0.97-1.02) (Figure 3). Statin use was associated with a lower risk for all-cause mortality (22,395 vs 23,196 events, HR 0.91, 95% CI 0.90-0.93). The relatively small E value = 1.34 suggests that little unmeasured confounding would be needed to produce this association between statin use and all-cause mortality.” The log-rank test related to Figure 3 should read P = .63. On page 3, under the subtitle “Subgroup analyses”, the text should read: “Regardless of statin use, younger age (<50 years) and active kidney transplant waitlist status correlated with a lower risk of the primary composite (<50 years vs ≥50 years, P < .0001, Figure 4A; waitlisted versus non waitlisted, P < .0001, Figure 4B). However, the association between statin use and the risk of the primary composite did not differ across age groups (P-interaction = .42, Figure 4A) or waitlist status (P-interaction = .07, Figure 4B). Evaluating all 4 generated subgroups there were no associations between statin use and the primary outcome (<50 years and not waitlisted: HR 1.03, 95% CI 0.93, 1.14; ≥50 years and not waitlisted: HR 0.98, 95% CI 0.96, 1.01; <50 years and waitlisted: HR 1.18, 95% CI 0.99, 1.41; ≥50 years and waitlisted: HR 1.13, 95% CI 0.97, 1.31).” The log-rank test related to Figure 4A should read P = .42 and related to Figure 4B should read P = .07. There was no change in the conclusions of the study. The authors would like to apologize for any inconvenience caused.
AB - The authors regret that a typographical error and merge error was identified in the generation of the original dataset for this analysis. As a result, there is a change in the total event numbers for the primary outcome of fatal and nonfatal myocardial infarction or stroke and all-cause mortality. On page 3, under the subtitle “Primary and secondary outcomes”, the text related to these outcomes should read: “Over a median of 622 days (interquartile range spanning 299-1,224 days) in the propensity-matched population, statin use was not associated with the composite risk for fatal or nonfatal myocardial infarction or stroke (11,632 vs 11,047 events, hazard ratio [HR] 0.99, 95% CI 0.97-1.02) (Figure 3). Statin use was associated with a lower risk for all-cause mortality (22,395 vs 23,196 events, HR 0.91, 95% CI 0.90-0.93). The relatively small E value = 1.34 suggests that little unmeasured confounding would be needed to produce this association between statin use and all-cause mortality.” The log-rank test related to Figure 3 should read P = .63. On page 3, under the subtitle “Subgroup analyses”, the text should read: “Regardless of statin use, younger age (<50 years) and active kidney transplant waitlist status correlated with a lower risk of the primary composite (<50 years vs ≥50 years, P < .0001, Figure 4A; waitlisted versus non waitlisted, P < .0001, Figure 4B). However, the association between statin use and the risk of the primary composite did not differ across age groups (P-interaction = .42, Figure 4A) or waitlist status (P-interaction = .07, Figure 4B). Evaluating all 4 generated subgroups there were no associations between statin use and the primary outcome (<50 years and not waitlisted: HR 1.03, 95% CI 0.93, 1.14; ≥50 years and not waitlisted: HR 0.98, 95% CI 0.96, 1.01; <50 years and waitlisted: HR 1.18, 95% CI 0.99, 1.41; ≥50 years and waitlisted: HR 1.13, 95% CI 0.97, 1.31).” The log-rank test related to Figure 4A should read P = .42 and related to Figure 4B should read P = .07. There was no change in the conclusions of the study. The authors would like to apologize for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85135563625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135563625&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2022.06.009
DO - 10.1016/j.ahj.2022.06.009
M3 - Comment/debate
C2 - 35934528
AN - SCOPUS:85135563625
SN - 0002-8703
VL - 253
SP - 99
EP - 100
JO - American heart journal
JF - American heart journal
ER -